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Editorial on the Research Topic
The Immunology of Sepsis—Understanding Host Susceptibility, Pathogenesis of Disease, and
Avenues for Future Treatment
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response
to infection (1). Most recent estimations suggest that sepsis affects about 49 million people and
accounts for around 11 million deaths each year worldwide (2), making it one of the leading
causes of preventable death in all age groups. Sepsis is a health priority according to the World
Health organization (3), which provided recommendations to improve the prevention, diagnosis
and management of sepsis. Although sepsis mortality has decreased over the past two decades
(4, 5), the incidence of sepsis continues to rise due to a higher number of patients with complex
conditions such as immunosuppression as well as an increase in more elderly people. A basic
requirement for effective sepsis management is timely and appropriate antimicrobial therapy (6, 7).
With the increase of infections caused by multidrug resistant bacteria, the advances made toward
rapid multidrug testing to enable personalized antimicrobial therapies is promising (Sun et al.).
However, a major obstacle to improving sepsis outcomes is the lack of knowledge on the intricate
interplay between host defense, infection, and pathogen virulence, as well as timing and nature
of interventions. Over the past decade, our understanding of sepsis has evolved from the earlier
concept of sepsis as a result of an excessive inflammatory response to the current notion that
sepsis outcomes are more likely related to the dynamic balance between pro-inflammatory and
counteracting anti-inflammatory mechanisms. To this end, animal models and a number of human
observational studies have paved the way toward precision trials on immunotherapy for sepsis
(Zijlstra et al.).
The aim of the Frontiers in Immunology Research Topic “The Immunology of
Sepsis–Understanding Host Susceptibility, Pathogenesis of Disease, and Avenues for Future
Treatment” was to collect state-of-the art articles and reviews on the role of the host immune
system affecting susceptibility, presentation, and outcome of sepsis. We hereby provide an
overview of this Frontiers in Immunology topic which includes 11 original articles, 13 review
articles, 1 commentary, and 1 case report.
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SUSCEPTIBILITY TO SEPSIS
Sepsis susceptibility may result from maturational, genetic, or
acquired alterations of the immune system. The incidence of
sepsis is highest in newborns (8), and an increasing body of
studies characterize distinct patterns of immune responses in
this age group compared to children and adults. Schneider et al.
for example, demonstrate that neonatal macrophages express
substantially less tumor necrosis factor compared to adult cells,
regulated through the transcription factor interferon regulatory
factor 5 (IRF5).
Considering how few patients develop sepsis in comparison
to the exposed population, there is biological plausibility and
epidemiologic evidence for underlying genetic mechanisms
affecting susceptibility to sepsis (9, 10). These may affect both
very rare variants associated with extreme phenotypes (11) and
common variants that may be of relevance at the populational
level (12). Deficiency in mannose-binding lectin (MBL) emerged
two decades ago as a promising candidate to investigate this
hypothesis (13). Although polymorphisms affecting MBL serum
levels are common and the role of complement in host defenses
against bacterial infections is well known, previous reports on
the relevance of MBL deficiency in susceptibility to infection
remained conflicting (14). Using a well-phenotyped prospective
intensive care unit cohort, Levy et al., genotyped 420 pediatric
patients with influenza-associated organ dysfunction for variants
in the MBL2 gene expected to result in low serum MBL levels.
No clear relationship was observed between genetic variants and
overall outcomes in the cohort, neither in within-cohort, nor in
trio or control analyses. Interestingly, and similar to a previous
study, low-MBL producing variants were more common in a
subset of fatal cases with methicillin-resistant Staphylococcus
aureus (MRSA), but the relevance of this finding remains to be
confirmed in larger studies.
HOST-PATHOGEN INTERACTION
Children are prone to severe infections caused by encapsulated
bacteria such as Streptococcus pneumoniae, Streptococcus
agalactiae (Group B streptococcus, GBS), Neisseria meningitis
and Haemophilus influenzae. The polysaccharide capsule is a
key bacterial virulence factor hindering opsonophagocytosis and
complement-mediated bacteriolysis. However, it also represents
an effective target for vaccine development. In his review,
Sadarangani describes the mechanisms of vaccine-induced
protection and illustrates successful examples of pneumococcal
and meningococcal capsular conjugate vaccines, while challenges
remain in the development of effective vaccines against non-type
b H. influenzae and GBS that also carry polysaccharide capsules.
The article by Kadhim et al., demonstrates a novel potential
drug candidate to block staphylococcus enterotoxin-induced
organ damage. Finally, Deng et al. investigate mechanisms of
complement evasion in streptococcal strains.
Very timely considering the current coronavirus disease
2019 (COVID-19) pandemic, and giving credit to an often
overlooked problem, Lin et al., provide a thorough overview of
the epidemiology and pathogenesis of viral sepsis with a focus
on herpes simplex, influenza, and dengue viruses, as well as
entero- and parechoviruses. Recognition of a viral origin of sepsis
could allow targeted treatment and reduce the unnecessary use
of antibiotics.
UNDERSTANDING THE DYSREGULATED
HOST RESPONSE TO INFECTION
While the concept of a “dysregulated host response to infection
leading to organ dysfunction” in sepsis is broadly accepted,
our understanding of the underlying mechanisms remains very
limited. The contributions to this Frontiers topic shed light on a
number of pathways that are likely involved.
Previous studies have shown that a subgroup of septic
children and adults reveal similar patterns to patients with
hemophagocytic lymphohistocytosis (HLH), or macrophage
activation syndrome (MAS) such as cytokine storm,
hyperferritinemia, and multi-organ dysfunction. This entity
has been termed macrophage activation-like syndrome (MALS).
Karakike et al. provide an overview of the available evidence on
this topic, while the results of the first randomized clinical trials
(RCTs) on MALS are eagerly awaited. Zarjou et al. assessed the
inhibitory role of myeloid ferritin heavy chain and ferritin light
chain in a mouse model on nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) activation, illustrating a
potential immunomodulatory role of ferritin light chain.
More recently, insight into pro- and anti-inflammatory
responses to the exposure of pathogen- and damage-associated
molecular patterns (PAMPs and DAMPs) suggest a dynamic
and heterogenous process (15). A fascinating research area
in this regard relates to epigenetic processes affecting gene
expression during sepsis. Cross et al. provide an overview on
the literature on this topic. They summarize the rapidly growing
number of mainly laboratory studies indicating that epigenetic
mechanisms are thoroughly perturbed during sepsis, and are
related to endothelial dysfunction and immunosuppression.
These observations may open up new treatment options, such
as drug interventions with histone deacetylase inhibitors for
which pre-clinical animal studies suggest a potential benefit.
It will be interesting to see whether candidate drugs progress
to clinical studies on immune modulation in sepsis in the
coming decade. Another possible drug approach that could
support a more balanced immune response is the blocking of
the Src family of tyrosine kinases with dasatinib, a drug for the
treatment of chronic myeloid leukemia and acute lymphoblastic
leukemia. Indeed, Gonçalves-de-Albuquerque et al. report
promising results of using dasatinib in a mouse model of
polymicrobial sepsis.
Several other proteins and cells represent both encouraging
biomarkers and therapeutic targets for future strategies to combat
sepsis. For example, Schrijver et al. report that myeloid-derived
suppressor cells (MDSCs) are a heterogenous group of immature
cells that expand in a number of conditions including sepsis.
MDSCs suppress immune responses of different cell types in
the early and late phases of sepsis, and pre-clinical studies
show distinct patterns of expansion of MDSC subpopulations
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Observational studies have already reported an association
between high proportions of blood MDSCs and poor outcome in
sepsis patients. In a mouse model, Bomans et al. have elucidated
mechanisms involved in the functional reprogramming of naïve
bone marrow monocytes after sepsis, which lead to a “memory”
of the innate immune system.
Other articles submitted to this Research Topic illustrate
a number of recent discoveries of cells and pathways that
contribute to the host response to sepsis. Yin et al., demonstrate
that phosphatase regenerating liver 2 (PRL2) regulates the
generation of reactive oxygen species in macrophages
and thereby contributes to bactericidal activity. Sjaastad
et al., assessed the response to polymicrobial sepsis using a
mouse model and observed features consistent with chronic
immunoparalysis, measured by reduced antigen-specific T
cell-dependent B cell responses.
Although the intestinal system has not been commonly
considered in organ dysfunction scores (1), it represents an
extraordinary body surface area containing a high density of
lymphatic tissues and immune cells. The regulation between the
host immune system and intestinal pathogens as well as bacterial
translocation play a key role in the dynamic processes during and
after shock. Increasing our understanding of these events may
point to ways for secondary interventions, as summarized in the
review by Haussner et al., on the role of the intestinal mucosa
during sepsis. Expanding from this work, the importance of
intestinal microbiota in sepsis is explored in the excellent review
by Haak et al. shedding light on the therapeutic potential of
microbiome-modifying strategies for prevention and treatment
of sepsis and sepsis-related late mortality.
BIOMARKERS, MONITORING THE
IMMUNE SYSTEM, AND THE FUTURE
OF IMMUNOMODULATION IN SEPSIS
The immune status of patients with sepsis is subject to rapid
progression, and hyperinflammation and immunoparalysis may
change dynamically. The failures to characterize the predominant
immunological phenotype of sepsis patients coupled with
considerable disease and patient heterogeneity represent major
obstacles to develop effective immunomodulation-based trials.
Peters van Ton et al. discuss the critical need for accurate
monitoring of associated immune dysregulation to select
patients more likely to benefit from targeted immunomodulatory
interventions, and to facilitate enrolment in clinical studies
toward personalized medicine.
The initial response to infection includes activation of
innate immunity through soluble and cell-bound pattern
recognition receptors. Porte et al. for example, review the
available evidence on the role of the long pentraxin 3
(PTX3) in sepsis, a molecule with high homology with C-
reactive protein. PTX3 binds to various microorganisms and
has protective effects against sepsis in animal models. In
human studies, high blood levels of PTX3 are associated with
sepsis severity, suggesting a potential use as a biomarker.
Furthermore, Tipoe et al. performed a systematic review and
meta-analysis of plasminogen activator inhibitor-1 (PAI-1) in
sepsis. PAI-1 level is increased in patients, and may be used
as a predictor of disease severity and all-cause mortality
in sepsis.
Low expression levels of human leukocyte antigen D related
(HLA-DR) by CD14 leukocytes are increasingly used as a marker
of sepsis-induced immunosuppression. Tamulyte et al. report on
a prospective cohort assessing monocyte HLA-DR by a point-
of-care test. They demonstrate the principle feasibility of the
approach, which may help to identify patients with a higher risk
of worse outcomes due to sepsis. Excitingly, the development of
novel assays for immune profiling patients with severe infections
has made huge progress and is anticipated to enable personalized
medicine trials in the very near future.
The most widely studied immunomodulatory drugs in sepsis
are corticosteroids. A large number of high quality RCTs in
critically ill adults are available, as nicely reviewed by Heming
et al. The immunomodulatory effects of statins have been
recognized for some time. Braga Filho et al. used a mouse model
of CLP to demonstrate the positive impact on simvastatin on
survival and immune modulation.
CONCLUSIONS
In summary, the knowledge on the pathophysiology of sepsis has
expanded in recent years. Many original and review article in
this Research Topic describe experimental and clinical studies
pointing to new candidates for biomarkers and interventions,
which may ultimately pave the way toward personalized care
for sepsis. The availability of improved immunophenotyping
approaches, coupled with a number of candidate drugs currently
under investigation is promising. The marked heterogeneity of
sepsis advocates for highly selective interventions, targeted at
populations selected for patients who are more likely to respond
to, and to benefit from therapeutic interventions. The success
of this endeavor will depend on the capability to incorporate
effective strategies for patient selection and targeted treatment
allocation. As a promising sign, a number of consortia have
recently been launched to advance personalized immunotherapy
in sepsis. As nicely discussed by Talisa et al. trials using
adaptive enrichment and response adaptive randomization may
be best suited to tackle the challenges of developing effective
treatments for clinical practice. Recently, large international
randomized, embedded, multifactorial adaptive platform trials
(originally developed in the field of cancer clinical research) have
been launched in infectious diseases and hopefully will boost
the efficiency and impact of sepsis research. These advances
may motivate further personalized medicine trials leading to
sustainable outcome improvements for this major killer disease.
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